All stock lists
Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
Healthcare · Drug Manufacturers - Specialty & Generic
0.65+0.08 (+13.99%)
Insider Score
––Not scored
AKBA Insider Score
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
AKBA Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 49.13 M | 53.54 M | 57.62 M | 58.77 M | 62.47 M | 57.34 M |
| Revenue Growth (YoY) | -21.36 % | -6.61 % | 23.92 % | 57.01 % | 43.13 % | 75.84 % |
| Cost of Revenue | 10.42 M | 12.62 M | 12.22 M | 9.70 M | 9.92 M | 7.63 M |
| Gross Profit | 38.70 M | 40.93 M | 45.41 M | 49.06 M | 52.55 M | 49.71 M |
| SG&A Expense | 28.17 M | 30.44 M | 26.09 M | 29.99 M | 26.55 M | 25.74 M |
| R&D Expense | 14.06 M | 14.81 M | 26.65 M | 14.63 M | 11.01 M | 9.75 M |
| Operating Expenses | 45.03 M | 45.62 M | 53.96 M | 44.62 M | 38.46 M | 36.20 M |
| Operating Income | -6.33 M | -4.70 M | -8.55 M | 4.45 M | 14.09 M | 13.51 M |
| Pretax Income | -8.84 M | -8.93 M | -11.23 M | 1.16 M | 247.00 K | 6.11 M |
| Tax Provision | 70.00 K | 126.00 K | 1.01 M | 615.00 K | 0.00 | 0.00 |
| Net Income | -8.91 M | -9.05 M | -12.24 M | 540.00 K | 247.00 K | 6.11 M |
| EPS (Basic) | -0.03 | -0.03 | -0.05 | 0.00 | 0.00 | 0.03 |
| EPS (Diluted) | -0.03 | -0.03 | -0.05 | 0.00 | 0.00 | 0.03 |
| Shares Outstanding | 269.60 M | 267.05 M | 265.37 M | 264.79 M | 262.57 M | 235.50 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.